If you suffer from keratoconus, your wait for progressive treatment is finally over. The FDA has approved corneal collagen cross-linking to strengthen weak corneas caused by keratoconus – and ultimately save vision. It may also reduce the need for corneal transplants for some patients.
At Mountain Valley Eye Institute, we are excited to offer keratoconus patients corneal crosslinking in Park City, UT, using the Glaukos KXL System. This treatment is now widely covered by medical insurance.
How KXL Works
During this 2-step process, our doctors apply a riboflavin solution (a form of vitamin-B2) to the eye, followed by controlled ultraviolet (UV) light exposure for up to 30 minutes. This process increases the amount of collagen cross-links in the cornea, making the cornea stronger, more stable and able to hold its shape. A single treatment may be all that is needed to improve vision.
There are two types of KXL:
- Epithelium-off: the thin outer layer of the eye’s surface is removed and liquid riboflavin eye drops are applied
- Epithelium-on (transepithelial): liquid riboflavin eye drops are applied directly to the eye, without removing the thin outer layer of the eye’s surface
Only the epithelium-off method is currently FDA-approved in the U.S. The riboflavin eye drops used in this process are a combination of proprietary Photrexa and Photrexa Viscous solutions.
While not a cure for the disease, this keratoconus treatment has been effective in slowing the progression of the disease and helping preserve vision. Some patients may still need to wear prescription glasses or contact lenses to achieve their best vision possible.
If you have been diagnosed with keratoconus, contact us today to schedule an eye exam with our keratoconus doctors in Park City and learn about this innovative treatment option.